Dawid Walerych69 found that in breast cancer, knocking down mutant p53 or proteasome activity leads to an increase in SRSF11 levels, suggesting that the mutant p53-proteasome axis may downregulate the expression or stability of SRSF11 through a specific mechanism. Here, TP53 is linked to breast carcinoma.